Sandoz Acquires Antifungal Agent From Astellas, Reinforcing Hospital Offering

  • Sandoz, a generic pharmaceuticals and biosimilar unit of Novartis AG NVS, has agreed to acquire worldwide product rights for systemic antifungal agent Mycamine (micafungin sodium, Funguard in Japan) from Astellas Pharma Inc ALPMF ALPMY.
  • Deal terms were not disclosed.
  • The deal is expected to conclude in 1H 2023.
  • Astellas reported Mycamine sales of JPY 18.9 billion ($135 million) for the year ending March 31, 2022. 
  • The announcement comes after Sandoz completed the acquisition of GSK Plc’s GSK cephalosporins portfolio in October 2021.
  • Sandoz CEO Richard Saynor said: “Acquiring this leading and respected global brand will significantly reinforce the Sandoz global hospital offering and complement our existing global leadership position in generic antibiotics.”
  • Mycamine is indicated for invasive candidiasis and esophageal candidiasis.
  • Price Action: NVS shares are down 0.59% at $91.67 on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechLarge CapM&ANewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!